Swedish Orphan Biovitrum AB

As of June 30, 2026, Swedish Orphan Biovitrum AB carries a market capitalization of 14.51B, placing it among publicly traded companies globally. Its enterprise value stands at 16.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Swedish Orphan Biovitrum AB's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Swedish Orphan Biovitrum AB has 347.29M shares outstanding.

As of June 30, 2026, Swedish Orphan Biovitrum AB trades at a trailing price-to-earnings ratio of 32.53. The price-to-sales ratio is 5.51, and the price-to-book ratio stands at 3.80.

As of June 30, 2026, Swedish Orphan Biovitrum AB trades at an EV/EBITDA multiple of 16.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.11 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Swedish Orphan Biovitrum AB trades at an EV/FCF ratio of 27.62, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 16.00B versus a market cap of 14.51B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Swedish Orphan Biovitrum AB maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Swedish Orphan Biovitrum AB posted a return on equity (ROE) of 12.08, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.85 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.42, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.70, useful for judging operating efficiency across full business cycles. The company generates approximately 1.40M in revenue per employee across its workforce of 1,876.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times Swedish Orphan Biovitrum AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Swedish Orphan Biovitrum AB recorded 103.55M in income tax expense. That works out to an effective tax rate of 18.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 547.02M, leaving 443.47M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 6, 2026, Swedish Orphan Biovitrum AB's stock has gained approximately 37.95% over the past 52 weeks. The 50-day moving average sits at 40.76, while the 200-day moving average is 38.32.

Over the twelve months ended June 30, 2026, Swedish Orphan Biovitrum AB generated 2.62B in revenue and converted that into 443.47M in net income, yielding earnings per share of 1.27. EBITDA reached 951.94M, while operating income came in at 671.88M.

As of June 30, 2026, Swedish Orphan Biovitrum AB holds 97.69M in cash and equivalents against 1.59B in total debt, resulting in a net debt position of 1.46B. Total book value stands at 3.82B, with working capital of -224.53M providing operational flexibility.

Swedish Orphan Biovitrum AB produced 674.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -94.89M in capital expenditures, free cash flow totaled 579.25M - equivalent to 1.68 per share.

Over the twelve months ended June 30, 2026, Swedish Orphan Biovitrum AB posted a gross margin of 77.17, reflecting its pricing power and cost economics. The operating margin of 25.64 and net profit margin of 16.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.97, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.99, meaning Swedish Orphan Biovitrum AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Swedish Orphan Biovitrum AB's most recent stock split took place on August 28, 2023.

As of June 30, 2026, Swedish Orphan Biovitrum AB has an Altman Z-Score of 6.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.